This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Oragenics, Inc.

Drug Names(s): OG 716, OG-716

Description: OG716 is an orally-active lantabiotic homolog generated from Oragenics’ Mutacin 1140 (MU1140) platform. MU1140, a type A lantibiotic, is a highly modified, strongly cationic, 22 amino-acid peptide antibiotic found to target Gram positive bacteria. Type A lantibiotics kill rapidly through the formation of voltage-dependent membrane channels.

Deal Structure: Intrexon and Oragenics
In June 2012, Oragenics and Intrexon announced the formation of a global exclusive channel collaboration through which Oragenics intends to develop and commercialize lantibiotics as active pharmaceutical ingredients (API) for the treatment of infectious diseases in humans and companion animals.

Under terms of the transaction agreements, Oragenics will receive an exclusive, worldwide license to utilize the products of Intrexons modular genetic engineering platform for the development of API and drug products involving the direct administration to humans or companion animals of a lantibiotic for the prevention or treatment of infectious disease. Intrexon will apply its proprietary platforms and technologies, including UltraVector, DNA and RNA MOD engineering, protein engineering, transcription control chemistry, genome engineering, and cell system engineering, to Oragenics lantibiotics program. Oragenics is responsible for funding the further...See full deal structure in Biomedtracker

Partners: Intrexon Corporation

OG716 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug